The Next Era in U.S. Healthcare Policy & Access Series
Home / Intelligence / Webinars / Policy Change Through Another Lens: Impact on Health Plans and Implications for Biopharma
Available On Demand
The second webinar in our “Next Era in U.S. Healthcare Policy & Access” series looks at the evolving healthcare policy landscape from a different perspective.
Join us as we explore how U.S. policy changes are impacting health plans, how health plan decision-making needs to adapt, and what this means for biopharma companies. The webinar will feature an engaging panel discussion hosted by Max Hunt, Partner at Trinity Life Sciences, with special guests Stephen George and Matthew Hayes, clinical and actuarial experts at Milliman.
Key Webinar Topics
- How have health plans been adapting in light of recent U.S. policy reform, including Part D redesign introduced in the Inflation Reduction Act (IRA)?
- What key opportunities and challenges do health plans face in the next two to three years? How does this differ across Commercial, MA-PD and PDP offerings?
- How should biopharma companies expect that health plan behavior may change in the coming years?
- What challenges may be posed to driving access to innovative drugs, especially in competitive categories?
- What should biopharma companies do to adapt to these landscape shifts and how can they better understand their health plan customers?
In Case You Missed It
Watch the first webinar in our “Next Era in U.S Healthcare Policy & Access Series”
Featuring
Complete the form below to view the on-demand webinar.
We would contact you in accordance with our Privacy Policy, which we invite you to visit for details about our data privacy practices, including, where appropriate, how you may access and correct the personal data we store or withdraw consent to the collection, use or disclosure of such information. We will not share your email address or personal information. If you would like to opt out in the future, please email _compliance@trinitylifesciences.com.
This webinar will be hosted within the ON24 platform, which requires the usage of Javascript and Cookies. Please see ON24’s Privacy Policy for more information.
Related Intelligence
Webinars
Virtual Demo | HTA Vision with GenAI
March 13, 2025 | 11:00 – 11:30 AM ET
Join Trinity Life Sciences for a virtual demo where value, access and pricing experts Max Hunt and Andreia Ribeiro will demonstrate Trinity HTA Vision, our cloud-based dashboard with GenAI capabilities. It is not enough to know what the health technology assessment (HTA) decisions are and when they are made—with the landscape continually evolving, analogues and future […]
Sign Up Now
Blog
Learnings to Kick-Start 2025: Health Equity
Health equity continues to be a hot topic in the life sciences industry. ISPOR EU sessions addressed several key questions surrounding the impact of health equity on HTA decision-making, the methodologies that should be employed, and the opportunities and challenges of incorporating health equity into health technology assessment (HTA). Ahead of ISPOR EU, Trinity’s HTA […]
Read More
Blog
Maximum Fair Price Round 2: Passing the Baton
On January 20, 2025, CMS announced the set of fifteen drugs targeted for the second round of Maximum Fair Price (MFP) “negotiations” under IRA. With the outcomes of the first price “negotiations” announced only last August, the IRA MFP process is still in its early development and there remains uncertainty over how it will evolve […]
Read More